Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Barium enema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Barium enema. Displaying page 1 of 1.
    EudraCT Number: 2005-003319-64 Sponsor Protocol Number: S3B40042 Start Date*: 2007-07-05
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006118-17 Sponsor Protocol Number: B3I105940 Start Date*: 2006-08-17
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002976-14 Sponsor Protocol Number: CRI103143 Start Date*: 2006-09-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of ...
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000733-12 Sponsor Protocol Number: SPD476-301 Start Date*: 2004-07-14
    Sponsor Name:Shire Pharmaceutical Development Inc
    Full Title: A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 g...
    Medical condition: Subjects who have newly diagnosed or have a diagnosis of relapsing (relapses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002685-38 Sponsor Protocol Number: 2-2 Start Date*: 2005-08-05
    Sponsor Name:Yakult Honsha Co
    Full Title: Randomised controlled trial of metronidazole and probiotic preparation versus placebo in the treatment of irritable bowel syndrome
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000848-24 Sponsor Protocol Number: SB-223412/068 Start Date*: 2004-10-26
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023003 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021879-85 Sponsor Protocol Number: 10050 Start Date*: 2010-09-08
    Sponsor Name:University of Nottingham
    Full Title: Mode of action of Moviprep:impact on distribution of intestinal fluid and colonic microbiota
    Medical condition: for bowel cleansing prior to any clinical procedure requiring a clean bowel, e.g, bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002145-21 Sponsor Protocol Number: 2007003 Start Date*: 2007-12-21
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation
    Medical condition: Chronic Idiopathic Constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063582 Constipation chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002048-25 Sponsor Protocol Number: IBD-001 Start Date*: 2005-07-20
    Sponsor Name:SBL Vaccin AB
    Full Title: A pilot study to investigate the use of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease.
    Medical condition: Inflammatory Bowel Disease (IBD) is the comprehensive term for disorders involving chronic inflammation in the gastrointestinal tract, often the small intestine and colon. It is believed to be a di...
    Disease: Version SOC Term Classification Code Term Level
    10011401 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004896-20 Sponsor Protocol Number: SPD476-314 Start Date*: 2008-05-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence...
    Medical condition: Treatment of Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-003280-41 Sponsor Protocol Number: IBS-02/07 Start Date*: 2007-11-08
    Sponsor Name:SOFAR SPA
    Full Title: A randomised controlled multicenter trial assessing the efficacy and safety of mesalazine therapy in patients with irritable bowel syndrome.
    Medical condition: Irritable Bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001664-34 Sponsor Protocol Number: 12028-FC-SS Start Date*: 2013-08-30
    Sponsor Name:Belfast HSC Trust [...]
    1. Belfast HSC Trust
    2. Queens University Belfast
    Full Title: Vit-D in CRC - A Randomised Double Blind Placebo-Controlled Clinical Trial Of a Single Oral Cholecalciferol Treatment Against Surrogate End Point Biomarkers (SEBs) In Colon Cancer (CRC) Patients
    Medical condition: Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004043-21 Sponsor Protocol Number: 16-OBE2109-016 Start Date*: 2018-10-17
    Sponsor Name:ObsEva SA
    Full Title: An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.
    Medical condition: Rectovaginal endometriosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002063-87 Sponsor Protocol Number: Protocol Number 291-415 Start Date*: 2006-03-16
    Sponsor Name:PDL BioPharma, Inc
    Full Title: A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease: Version SOC Term Classification Code Term Level
    9.0 10045365 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) AT (Prematurely Ended) BE (Completed) CZ (Completed) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003482-17 Sponsor Protocol Number: 291-418 Start Date*: 2006-03-03
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) ES (Ongoing) GR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001600-38 Sponsor Protocol Number: 27018966IBS3001 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001601-24 Sponsor Protocol Number: 27018966IBS3002 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004895-37 Sponsor Protocol Number: SPD476-313 Start Date*: 2007-12-19
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence...
    Medical condition: Treatment of Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017044-13 Sponsor Protocol Number: SPD476-409 Start Date*: 2010-06-30
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) HU (Completed) BE (Completed) CZ (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:56:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA